Trial · NCT03205150
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Alanine Aminotransferase (ALT) at Week 12 | Baseline, Week 12 | Pharmacodynamics (PD) analysis set: included all participants with available PD data, who received any study drug and had valid measurements for the outcome measure | Units per Liter (U/L) | MEAN |
| SECONDARY | Change From Baseline in Percent Liver Fat at Week 12 | Baseline, Week 12 | Pharmacodynamics (PD) analysis set: included all participants with available PD data, who received any study drug and had valid measurements for the outcome measure | Percentage of Liver Fat | MEAN |
| SECONDARY | Percent Change From Baseline in Total Body Weight at Week 12 | Baseline, Week 12 | Pharmacodynamics (PD) analysis set: included all participants with available PD data, who received any study drug and had valid measurements for the outcome measure | percentage change | MEAN |
| SECONDARY | Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Enhanced Liver Fibrosis Test (ELF) Score at Week 12 | Baseline, Week 12 | Pharmacodynamics (PD) analysis set: included all participants with available PD data, who received any study drug and had valid measurements for the outcome measure | scores on a scale | MEAN |
| SECONDARY | Change From Baseline in the Concentration of Hyaluronic Acid at Week 12. | Baseline, Week 12 | Pharmacodynamics (PD) analysis set: included all participants with available PD data, who received any study drug and had valid measurements for the outcome measure | ug/L | MEAN |
| SECONDARY | Change From Baseline in the Concentration of Procollagen Type Iii N-Terminal Peptide (PIIINP) at Week 12. | Baseline, Week 12 | Pharmacodynamics (PD) analysis set: included all participants with available PD data, who received any study drug and had valid measurements for the outcome measure | ug/L | MEAN |
| SECONDARY | Change From Baseline in the Concentration of Tissue Inhibitor Of Metalloproteinase 1 (TIMP-1) at Week 12. | Baseline, Week 12 | Pharmacodynamics (PD) analysis set: included all participants with available PD data, who received any study drug and had valid measurements for the outcome measure | ug/L | MEAN |
| SECONDARY | Pharmacokinetics of LIK066: Observed Maximum Plasma Concentration (Cmax) Following Drug Administration | Day 56 (pre-dose and 1, 2, 4 and 6 hours post-dose) | Pharmacokinetics (PK) analysis set consisted of LIK066 treated patients. Placebo patients were excluded from the PK analysis | ng/mL | MEAN |
| SECONDARY | Pharmacokinetics of LIK066: Observed Maximum Time Duration of Maximum Concentration (Tmax) Following Drug Administration | Day 56 (pre-dose and 1, 2, 4 and 6 hours post-dose) | Pharmacokinetics (PK) analysis set consisted of LIK066 treated patients. Placebo patients were excluded from the PK analysis | hours | MEDIAN |
| SECONDARY | Pharmacokinetics of LIK066: Observed Area Under the Curve up to the Last Measurable Concentration (AUClast) Following Drug Administration | Day 56 (pre-dose and 1, 2, 4 and 6 hours post-dose) | Pharmacokinetics (PK) analysis set consisted of LIK066 treated patients. Placebo patients were excluded from the PK analysis | hour*ng/mL | MEAN |
| SECONDARY | Change From Baseline in Aspartate Aminotransferase (AST) at Week 12 | Baseline, Week 12 | Pharmacodynamics (PD) analysis set: included all participants with available PD data, who received any study drug and had valid measurements for the outcome measure | Units per liter (U/L) | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03205150/outcomes